CDK1 and breast cancer: In conclusion, the lncRNA CD2BP2‐DT is identified as a crucial driver of breast cancer cell proliferation through the YBX1/CDK1 axis, highlighting its potential as a promising biomarker and therapeutic target for breast cancer.